Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Growth hormone axis · Compound

CJC-1295 (with DAC)

Growth hormone-releasing hormone analogue that binds albumin in the blood, studied in small human trials for its effect on growth hormone and IGF-1 levels.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 20265 min read

The strongest evidence found for CJC-1295 (with DAC) comes from small human studies, and every finding below carries its evidence level.

What is CJC-1295 (with DAC)

CJC-1295 is a modified analogue of growth hormone-releasing hormone (GHRH 1-29). The form studied in people carries a reactive group that binds to albumin in the blood, which extends its half-life to several days and gives sustained rises in growth hormone and IGF-1. Browse the full peptide library for related compounds.

In people, the strongest evidence recorded in the evidence dataset is small human studies. Two small randomised, placebo-controlled, ascending-dose trials in healthy adults (J Clin Endocrinol Metab 2006) with growth hormone and IGF-1 readouts only; a phase 2 trial in HIV was terminated without results. The readouts were hormone levels, not body composition or health outcomes.

CJC-1295 without DAC (Mod GRF 1-29) lacks the albumin-binding group; the human trials described here studied the DAC form. Ipamorelin, which acts on the ghrelin (growth hormone secretagogue) receptor, and tesamorelin, another growth hormone-releasing hormone analogue, have their own pages.

How it works

GHRH receptor: CJC-1295 targets the GHRH receptor (pituitary), the receptor through which growth hormone-releasing hormone signals growth hormone release. In the small human trials, one injection raised growth hormone levels.

Albumin binding: the DAC form carries a reactive group that binds albumin in the blood, which extends its half-life to several days.

IGF-1: in the same small human trials, the rise in growth hormone was accompanied by a rise in IGF-1, the hormone the liver produces in response to growth hormone.

Benefits studied

  • Sustained growth hormone and IGF-1 rise

    Small human studies

    Two small placebo-controlled trials in healthy adults aged 21 to 61 found one injection of the DAC form of CJC-1295 raised growth hormone 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days. Source: J Clin Endocrinol Metab 2006

  • Growth hormone pulses preserved

    Small human studies

    A non-randomised study of healthy men aged 20 to 40 found trough growth hormone 7.5-fold higher and IGF-1 45% higher a week after CJC-1295, with pulse frequency and size unchanged. Source: J Clin Endocrinol Metab 2006

  • Growth in growth hormone-deficient mice

    Animal and cell

    In mice lacking growth hormone-releasing hormone, 5 weeks of CJC-1295 produced normal body weight and length. This is animal evidence only. Source: Am J Physiol Endocrinol Metab 2006

Side effects reported

No human trial in the datasets reports adverse-event rates for CJC-1295, whose human evidence is limited to small human studies (2 completed randomised trials identified). Without controlled data, its safety in people is unknown rather than established.

Regulatory status

FDA Philippines
Not publishedCould not be established: the FDA Philippines verification portal search timed out on 23 September 2026, retried the same day in a browser with the same result.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
No sponsor identified in any record read.

Checked 23 September 2026. Primary source

How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.

Who should not use CJC-1295 (with DAC)

FAQ

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form carries a reactive group that binds albumin in the blood, which extends its half-life to several days. CJC-1295 without DAC, also called Mod GRF 1-29, lacks that group. The human trials in the evidence dataset studied the DAC form.

What evidence exists for CJC-1295 with DAC?

The strongest human evidence for CJC-1295 in the evidence dataset is small human studies, with 2 completed human randomised controlled trials identified. Two small randomised, placebo-controlled, ascending-dose trials in healthy adults (J Clin Endocrinol Metab 2006) with growth hormone and IGF-1 readouts only; a phase 2 trial in HIV was terminated without results.

Is CJC-1295 registered in the Philippines?

FDA Philippines registration status could not be established; the Regulatory status section gives the reason and date. US FDA: No record found. See the regulatory status page.

Where to get CJC-1295 (with DAC) in the Philippines

Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. View the Primara Labs catalogue

The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.

View Supply Index

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 24, 2026

Related peptides

Updated